deltatrials

Her2/neu negative Trials in Columbus, United States

Conditions / Her2/neu negative / Columbus, United States

Her2/neu negative has been the subject of sustained clinical investigation across multiple research sites.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID Title Status Phase
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING
NCT02115282 Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic ACTIVE_NOT_RECRUITING

Related Pages